Frederic H. Moll - 14 Sep 2021 Form 3 Insider Report for PROCEPT BioRobotics Corp (PRCT)

Role
Director
Signature
/s/ Alaleh Nouri, Attorney-in-Fact for Frederic Moll
Issuer symbol
PRCT
Transactions as of
14 Sep 2021
Net transactions value
$0
Form type
3
Filing time
14 Sep 2021, 19:15:29 UTC
Previous filing
12 Jul 2021
Next filing
21 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PRCT Common Stock 152,631 14 Sep 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding PRCT Series B Convertible Preferred Stock 14 Sep 2021 Common Stock 45,586 Direct F1
holding PRCT Series C Convertible Preferred Stock 14 Sep 2021 Common Stock 89,840 Direct F1
holding PRCT Series D Convertible Preferred Stock 14 Sep 2021 Common Stock 108,214 Direct F1
holding PRCT Series E Convertible Preferred Stock 14 Sep 2021 Common Stock 9,104 Direct F1
holding PRCT Series F Convertible Preferred Stock 14 Sep 2021 Common Stock 16,974 Direct F1
holding PRCT Series G Convertible Preferred Stock 14 Sep 2021 Common Stock 60,172 Direct F1
holding PRCT Stock Option (Right to Buy) 14 Sep 2021 Common Stock 5,263 $0.8550 Direct F2
holding PRCT Stock Option (Right to Buy) 14 Sep 2021 Common Stock 26,315 $4.51 Direct F3
holding PRCT Stock Option (Right to Buy) 14 Sep 2021 Common Stock 26,749 $1.33 Direct F2
holding PRCT Stock Option (Right to Buy) 14 Sep 2021 Common Stock 52,631 $5.46 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series A Preferred Stock , Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock and Series G Preferred Stock (collectively, the "Preferred Stock") will convert automatically into one share of Common Stock upon the closing of the Issuer's initial public offering. These shares have no expiration date.
F2 Stock option is fully vested and exercisable.
F3 The Stock option was granted on April 26, 2018 and vests on each monthly anniversary of the grant date over a 4 year period, subject continued employment or service to the Issuer through the applicable vesting date.
F4 The Stock option was granted on March 22, 2021 and vests on each monthly anniversary of the vesting commencement date over a 4 year period, subject continued employment or service to the Issuer through the applicable vesting date.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney